Background:
The presence of calprotectin in faeces is directly proportional to neutrophil migration towards the intestinal tract. The potential strength of faecal calprotectin assessment is that it is a direct measure of mucosal inflammatory activity, and levels in the stool seem to be unaffected by a variety of non-intestinal conditions, which may result in an elevation of the systemic inflammatory markers. Aim: To review the diagnostic accuracy of faecal calprotectin determination 1) to distinguish organic from functional disorders in symptomatic patients, and 2) for the diagnosis of IBD. Methods: Bibliographical searches were performed in MEDLINE up to September 2007 looking for the following words (all fields): ("inflammatory bowel disease" OR "Crohn' s disease" OR "ulcerative colitis") AND (calprotectin OR faecal marker). The mean sensitivity and specificity of faecal determination was calculated and expressed as weighted mean (and corresponding 95% confidence interval; 95% CI) to make due allowance for the number of patients included in each study. Subanalyses were performed depending on the IBD type: ulcerative colitis (UC) vs. Crohn' s disease (CD). Results: 1) Thirteen studies, including a total of 2475 patients, measured faecal calprotectin concentrations aiming to distinguish organic from functional intestinal disease in symptomatic patients. Mean sensitivities and specificities of 83% (95% CI, 81-84%) and 84% (95% CI, 82-85%), respectively, were calculated. 2) Fourteen studies, including a total of 754 patients, evaluated the diagnostic precision of faecal calprotectin for the diagnosis of IBD. In most of these studies, symptomatic patients with IBD or irritable bowel syndrome, in addition to controls, were included. Mean sensitivities and specificities of 80% (95% CI, 77-82%) and 76% (95% CI, 72-79%), respectively, were calculated for the diagnosis of IBD (taken together UC and CD). When a subanalysis was performed depending on the IBD type, a slightly higher accuracy was calculated for CD [sensitivity 83% (95% CI, 80-87%), specificity 85% (95% CI, 81-89%)] than for UC [sensitivity 72% (95% CI, 66-79%), specificity 74% (95% CI, 67-80%)]. Conclusion: Faecal calprotectin has a good diagnostic precision for distinguishing organic from functional intestinal disease in symptomatic patients, and also for separating IBD from non-IBD diagnoses, providing better results than those previously reported for the classically recommended systemic inflammatory markers such as erythrocyte sedimentation rate, C-reactive protein, anti-neutrophil cytoplasmic antibodies, and anti-Saccharomyces cerevisiae antibodies. 
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Background and aim:
Previous studies demonstrated that inflammatory bowel disease (IBD) is related to a decrease in quality of life but there are no data available on its subsequent impact on the patients' disease-related behavior. It is presumable that the disease-related decreased quality of life may result in a decreased patients' compliance, disturbed relationship with the physician and absence of appropriate fight or flight behavior, which in turn diminishes the chances on therapeutic success and amelioration of quality of life. The aim of this study was to assess the disease-related behavior of IBD patients with a decreased quality of life. Methods: This patient empowerment study has been performed in collaboration with the Dutch patients' association of Crohn' s disease and Ulcerative Colitis (CCUVN). Patients were asked to complete anonymously an online, patient based questionnaire, which was created by a working group of the CCUVN. The questionnaire comprised questions concerning the disease, the impact of the disease and limitations they experience as a consequence of this disease. Statistical analysis was performed using chi-square tests. Results: In total 1067 patients completed the questionnaire, 617 (57.6%) Crohn' s Disease (CD), 450 (42.2%) ulcerative colitis (UC). 46.8% had ≤8 yrs duration of disease, the majority of patients was female (66.5%) and the mean age was 43 yrs (SD 13,97). 531 patients (49.8%) responded to have a decreased quality of life. Regarding patients' disease-related behavior: patients with a decreased quality of life more often try to relax and to avoid stress and anxiousness (p=0.007). A decreased quality of life influences patients' experience of their ability to do the activities they would like to do in life (p<0.01). The disease is limiting patients in both professional aspects of life, like work (31,4%) and school (12,9%), as well as in family aspects (26,7%), eating (33.6%) and social activities like going out (34%), holidays (38%) and playing sports (37,7%). Therapy adherence is not influenced by a worse quality of life (p=0.244), although use of medication and adverse side effects itself were in fact associated with a worse quality of life (p<0.01). A decrease in quality of life does not disturb the relationship with the treating physician (p=0.676).
Conclusions:
In this large patient empowerment study patients do show avoidance behavior as a consequence of a decreased quality of life, but not as complete avoidance as expected. Surprisingly, therapy adherence and relationship with the physician are not influenced by the decreased quality of life. In a multivariate analyze, A1 (odds ratio 2.5, 95% confidence interval 1.6-4.1 for steroid intake and 2.6; CI 1.6 -4.2, for imunosupression) and A2 (1.6; CI 1.3 -2.0, for steroid intake and 1.5; CI 1.6-2.1 for imunosupression) were independently associated with steroid intake at least once during any given year and with immunosupression. Patients L3+L34 were associated with steroid intake (1.8; CI 1.4-2.2) and imunosupression (1.8; CI 1.4-2.3). B2 + B2p patients were independently associated with steroids intake. The groups related with bdominal surgery are: B2+B2p (10.5; CI 7.6-14.5), B3+B3p (9.4; CI 6.2-14.3), patients with abdominal abscesses (3.7; CI 2.3-5.8), abdominal fistulas (2.5; CI 1.6-3.9) and steroid resistance (5.3; CI 2.7-10.3). In contrast, L2+L2p group (0.6; CI 0.5-0.8) and patients who had taken at least once steroids (0.5; CI 0.3-0.7) were negatively associated with abdominal surgery. Conclusions: In Portuguese patients it was possible to identify different phenotypes with different requirement of steroids, immunosuppressants and surgeries. Administration of 5-aminosalicylic acid (5-ASA)-containing drugs is used in the treatment of acute inflammatory bowel disease and in the maintenance of the clinical remission. The effect of 5-ASA is believed to be due to a local action, so the site and the amount of drug release are highly important. Aims: to compare two different high-performance liquid chromatography (HPLC) methods to measure 5-ASA concentration in intestinal mucosa of patients treated with 5-ASA. Methods: the study was performed in collaboration with Giuliani Company. The HPLC system consisted of a Waters 515 pump, a Coulochem III 5300 ESA detector with a 5011A analytical cell; the electrode potentials were +250 mV and +750 mV. The HPLC column was a Macherey Nagel Nucleosil C18, 250 x 4.6 mm, 10µm, operating at 0.5 mL/min flow rate. Two mobile phases (MP) were compared: 1) 50 mM sodium acetate, 50 mM sodium citrate, 2% 2-propanol, 8% methanol, pH, 2.5; 2) 10 mM Na2HPO4, 0.1 mM EDTA, 0.1 M citric acid, 0.2 mM heptanesulfonic acid-methanol (90:10, v/v), pH 3. Tissues were homogenized in 0.2 M perchloroacetic acid, 100 µM EDTA, 100 µM sodium metabisulphite for MP 1, or in methanol for MP 2, both containing 1 µg/ml 3,4-dihydroxybenzylamine (DHBA) as the internal standard. 5-ASA calibration curve was obtained with blank mucosa spiked with scalar amounts of 5-ASA and 20 ng DHBA and plotting their peak-area ratios to 5-ASA concentrations. Samples were taken at surgery from seven 5-ASA treated and two not treated patients. Results: Using MP 1) 5-ASA and DHBA were not chromatographically resolved while using MP 2) two peaks were observed at 8,3 min (5-ASA) and at 9,2 min (DHBA). The mean recovery was ∼80%. Data were linear and reproducible in the range of concentration of interest (30-3000 ng/ml). Not-treated patients samples did not show any 5-ASA peak, while the chromatogram of treated patients samples showed 5-ASA and DHBA peaks giving mean concentrations from 2,1 ± 0,6 to 10,25 ± 0,93 ng 5-ASA/mg of tissue. Another peak eluting at 11 min was detected in all 5-ASA samples but it did not correspond to any known 5-ASA metabolites (2,5-and 2,3-dihydroxybenzoic acid and N-acetyl-5-ASA). Conclusions: the presence of the ion pairing heptanesulfonic acid was necessary for a good chromatographic separation of 5-ASA on a non-polar C18 column: this ion pair reagent interacts with 5-ASA creating a non-polar complex that can be chromatographically resolved on a non-polar stationary phase. On the other hand, the use of MP 1) on a C18 column didn' t ensure enough selectivity to resolve 5-ASA and DHBA. Our method permits the determination of 5-ASA concentration in human intestinal mucosal samples. Introduction: Anti-tumour necrosis factor (TNF)-alpha therapies are effective in treating perineal fistulising Crohn' s disease. We prospectively evaluated the efficacy of infliximab, adalimumab and thalidomide in the treatment of perineal fistulising Crohn' s disease, and assessed the value of MRI to determine deep healing and influence duration of treatment. Aims and methods: Infliximab naïve patients received infliximab, while patients who had previously failed infliximab received adalimumab or thalidomide. Clinical fistula evaluation was performed at baseline and each 8 weeks. MRI was performed at baseline and weeks 34 and 52. Clinical healing, MRI assessment of fistula track healing, Crohn' s disease Activity Index (CDAI), and Perianal Crohn' s Disease Activity Index (PCDAI) were prospectively assessed. Results: 34 patients with perineal fistulas (29 anorectal and 5 anovaginal; median fistulas=2) were included. Median follow-up to date was 44 weeks (range 22-93). 19 patients received infliximab, 7 had adalimumab and 8 had thalidomide. 30 patients had concurrent luminal disease. Concurrent thiopurine was used in 17 of 19 infliximab, 1 of 7 adalimumab, and 3 of 8 thalidomide-treated patients. Adalimumab-treated patients had previously failed infliximab: 4 lost response, 2 anaphylaxis, 1 no response. At week 22, response (> 50% reduction draining fistulas) and complete fistula closure, respectively, was seen in 16 (84%) and 11 (58%) of 19 infliximab-treated patients, 4 (57%) and 1 (14%) of 7 adalimumab-treated patients, and 4 (50%) and 1 (13%) of 8 thalidomide-treated patients. Three patients on thalidomide stopped treatment at week 2 due to side effects. At week 34, 19 patients have had a repeat MRI. Of 15 patients with clinical response, MRI showed complete healing in 4, improvement in 8 and unchanged in 3 patients. Of 4 patients without clinical response, MRI showed improvement in 1 and unchanged in 3. At week 52, of 13 patients who have had a repeat MRI, fistulas remained healed in the same 4 patients who had healed at week 34, further improvement in 5, and unchanged in 4 patients, compared with MRI at week 34. Mean PCDAI reduced from 9 at baseline to 4 at last follow-up. Mean CDAI reduced from 257 at baseline to 152 at last follow-up (p<0.05). Conclusion: Anti-TNF therapy is highly effective in treating perineal Crohn' s fistulas. Limited preliminary data suggest that MRI may indicate when treatment can cease. In keeping with previous findings in luminal disease, in fistulising disease the use of a second antibody is proportionally less effective than the first. Fistula tracks are slower to resolve than clinical remission. Prolonged treatment is often required to achieve internal track resolution. Background: The internet is now the largest source of health information and is widely used by both patients and health professionals. The growing amount of uncontrolled information available on inflammatory bowel disease (IBD) makes an evaluation necessary. Aim and Methods: To assess the quality of IBD information on the internet we performed a search using the phrases`inflammatory bowel disease' ,`Crohn' s disease' and`ulcerative colitis' . The search terms were entered separately into the six most commonly used search engines: Google, Yahoo! Search, AOL, MSN search, AlltheWeb, and Altavista. The first 30 results were used for initial evaluation. Web sites were categorized as institutional, pharmaceutical, non-pharmaceutical commercial sites, charitable, support or alternative medicine. Web sites were evaluated for content quality using the validated DISCERN rating instrument. Based on the total DISCERN score the web sites were grouped into categories: excellent (63-75), good (51-62), fair (39-50), poor (27-38), and very poor (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . In order to assess readability we used Word processor Microsoft Word 2003 in which free text was scored by using the Flesch Reading Ease and the Flesch-Kincaid Grade Level score. The Flesch Reading Ease score rates text on a 100-point scale. A score between 60-70 has been recommended for health information. The Flesch-Kincaid Grade Level score rates text on a U.S. school-grade level (recommended level 6 to 8). Results: A total of 86 websites were evaluated: 33% were institutional, 6% pharmaceutical, 29% non-pharmaceutical commercial sites, 5% charitable, 21% support, and 7% alternative medicine. The DISCERN tool rated 16% of the sites as excellent, 26% good, 38% fair, 12% poor, and 8% very poor. The average rating for institutional websites was 48 (fair), pharmaceutical 38 (poor),
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